|Day's Range||54.58 - 54.68|
|52 Week Range||53.56 - 56.22|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.12%|
By Erin Bigley April 25, 2017 More and more investors are globalizing their bond portfolios these days—with good reason. But when it comes to reducing risk, active management is essential. The French presidential election is just one reason. Bond ...
Markets are positioned for a relatively high likelihood that Sunday’s first round of voting in France’s closely-watched, two-stage presidential election paves the way for either centrist candidate Emmanuel Macron or conservative Francois Fillon, a former prime minister, to win the second round. An upset could roil global markets, Mohamed El-Erian, chief economic advisor at Pimco parent Allianz, told Barron’s. In the event the second round pits far-right nationalist candidate Marine Le Pen versus Jean-Luc Mélenchon -- what El-Erian describes as a “notable if” -- he says markets would see an immediate spike in volatility. Surveys show a tight race between Le Pen and Macron, with Fillon and Mélenchon not far behind.
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) today announced that the Israel Investment Center, a unit of the Government of Israel's Ministry of Economy and Industry, approved a grant representing 20% of a NIS 20M budget to be utilized towards the construction of a factory for the production of Phase 3 and commercial batches of BiondVax's universal flu vaccine candidate M-001. The grant is subject to certain terms and conditions including those outlined under the Encouragement of Capital Investment Law 1959. Five completed Phase 1/2 and Phase 2 human clinical trials have shown the vaccine to be safe and immunogenic to multiple flu strains.